Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509694 | 0.88 | LMNA (0.30) | TSHR | |
| SCHEMBL1680605 | 0.86 | TSHR (0.32) | TSHR | |
| SCHEMBL1680269 | 0.86 | TSHR (0.42) | ALDH1A1TSHRMEN1THRBHTT | |
| SCHEMBL3151320 | 0.84 | CYP3A4 (0.33) | TSHRMEN1THRBHTTKMT2A | |
| SCHEMBL4881159 | 0.83 | TSHR (0.33) | TSHRTHRB | |
| SCHEMBL1023994 | 0.81 | ALDH1A1 (0.36) | ALDH1A1TSHR | |
| SCHEMBL9646025 | 0.81 | ALDH1A1 (0.36) | ALDH1A1TSHR | |
| SCHEMBL31515197 | 0.80 | TSHR (0.54) | ALDH1A1TSHRMEN1THRBHTT | |
| SCHEMBL20165967 | 0.80 | DNM1 (0.33) | ALDH1A1TSHRMEN1KMT2ACYP3A4 | |
| SCHEMBL21491326 | 0.78 | CYP3A4 (0.43) | ALDH1A1TSHRMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831096-B2 | Effective against both A and B forms of influenza; oral bioavailability | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| US-20040097471-A1 | Inhibitors of neuraminidases | ABBVIE INC. | 2004-05-20 | — | — | US | disclosed |
| EP-1358154-A2 | PYRROLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF NEURAMINIDASES | Abbott Laboratories (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6593314-B1 | Useful in the inhibition of neuraminidase enzymes from disease- causing microorganisms, especially influenza neuraminidase, pharmaceutical formulations containing same, processes and intermediates for preparing said compounds, | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| EP-1315698-A1 | PYRROLIDINES AS INHIBITORS OF NEURAMINIDASES | ABBOTT LABORATORIES (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6455571-B1 | ESPECIALLY, INFLUENZA NEURAMINIDASE. | ABBOTT LABORATORIES | 2002-09-24 | — | — | US | disclosed |
| WO-2001029050-A2 | CONDENSED PYRROLE DERIVATIVES AS NEURAMINIDASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001028981-A1 | 1-CYCLOHEXENE-1-CARBOXYLIC ACID AND 1-CYCLOHEXENE-1-CARBOXYLATES AS NEURAMINIDASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001028996-A2 | PYRROLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF NEURAMINIDASES | ABBOTT LABORATORIES (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-1999054299-A1 | PYRROLIDINES AS INHIBITORS OF NEURAMINIDASES | ABBOTT LABORATORIES (US) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097471-A1 | Inhibitors of neuraminidases | NEU1, NEU2, NEU4 | ALDH1A1 320/4885TSHR 1226/4885MEN1 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.